NCT05054621View on ClinicalTrials.gov

Immunogenicity of COVID-19 Vaccine on Heterologous Schedule

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions
Covid-19VaccineImmunogenicityReactogenicityHealthy
Interventions
BIOLOGICAL

Heterologous prime-boost schedule with AZD1222 and MVC-COV1901

Participants will be divided into two subgroups according to the intervals, 28-42 days and 56-70 days, between the prime and booster doses.

BIOLOGICAL

Homologous prime-boost schedule with two doses of AZD1222

Participants will be divided into two subgroups according to the intervals, 28-42 days and 56-70 days, between the prime and booster doses.

Trial Locations (1)

333

ChangGungMH, Taoyuan District

All Listed Sponsors
lead

Chang Gung Memorial Hospital

OTHER

NCT05054621 - Immunogenicity of COVID-19 Vaccine on Heterologous Schedule | Biotech Hunter | Biotech Hunter